Expanded access trials in Germany

Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.

• EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer NCT00338247·Expanded access·Approved for marketing·Novartis·Started 2006
• Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia NCT00302016·Expanded access·No longer available·Novartis Pharmaceuticals·Started 2006
• Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma NCT00130897·Expanded access·Approved for marketing·Pfizer·Started 2005
• A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 NCT00094029·Expanded access·Approved for marketing·Pfizer·Started 2004
• A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation NCT00149981·Expanded access·No longer available·Novartis Pharmaceuticals
• TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. NCT00245739·Expanded access·Approved for marketing·Tibotec Pharmaceuticals, Ireland
• The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs NCT00354627·Expanded access·Approved for marketing·Tibotec Pharmaceuticals, Ireland
• Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy NCT00655252·Expanded access·No longer available·Novartis Pharmaceuticals
• An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck NCT00684385·Expanded access·Approved for marketing·AstraZeneca
• A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 NCT01196208·Expanded access·No longer available·Seagen Inc.
• Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects NCT01508286·Expanded access·No longer available·Janssen-Cilag International NV
• Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy NCT01538680·Expanded access·No longer available·Bayer
• A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer NCT01626781·Expanded access·No longer available·AIO-Studien-gGmbH
• Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH) NCT01784562·Expanded access·No longer available·Bayer
• International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer NCT02065765·Expanded access·Approved for marketing·Eli Lilly and Company
• EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C NCT02097966·Expanded access·No longer available·Bristol-Myers Squibb
• Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL NCT02187354·Expanded access·No longer available·Amgen
• Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) NCT02389933·Expanded access·No longer available·Novartis Pharmaceuticals
• An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma NCT02568943·Expanded access·No longer available·Novartis Pharmaceuticals
• Extension Study of Drisapersen in DMD Subjects NCT02636686·Expanded access·No longer available·BioMarin Pharmaceutical
• A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease NCT02963350·Expanded access·Approved for marketing·BioMarin Pharmaceutical
• Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation NCT03906331·Expanded access·Approved for marketing·Eli Lilly and Company
• Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI) NCT04173013·Expanded access·No longer available·Impatients N.V. trading as myTomorrows
• Expanded Access Remdesivir (RDV; GS-5734™) NCT04302766·Expanded access·No longer available·U.S. Army Medical Research and Development Command
• Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) NCT04323761·Expanded access·Approved for marketing·Gilead Sciences